US · ENTA · BIOTECHNOLOGY
Enanta Pharmaceuticals, Inc. (ENTA) intrinsic value and stock valuation
$7.62as of 2026-11-21 · Mkt cap 400.41M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Enanta Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values ENTA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ENTA’s statements →
Enanta Pharmaceuticals, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Assembly Biosciences, Inc. (ASMB) $22.19
- Atea Pharmaceuticals, Inc. (AVIR) $3.96
- Prelude Therapeutics Incorporated (PRLD) $3.23
- Foghorn Therapeutics Inc. (FHTX) $1.72
- Pyxis Oncology, Inc. (PYXS) $1.81
- Voyager Therapeutics, Inc. (VYGR) $1.53
- Tenaya Therapeutics, Inc. (TNYA) $0.29
- Caribou Biosciences, Inc. (CRBU) $0.28
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $65.3M | $67.6M | $79.2M | $86.2M | $97.1M |
| Operating income | -$-85.35M | -$-121.69M | -$-137.21M | -$-123.84M | -$-109.57M |
| Net income | -$-81.89M | -$-116.05M | -$-133.82M | -$-121.75M | -$-79M |
| EPSd | -$-3.84M | -$-5.48M | -$-6.38M | -$-5.91M | -$-3.92M |
| Operating cash flow | -$-19.27M | -$-78.76M | -$-103.15M | -$-84.78M | -$-70M |
| Capital expenditure | -$-12.9M | -$-17.95M | -$-9.06M | -$-2.12M | -$-750K |
| Free cash flow | -$-32.17M | -$-96.71M | -$-112.21M | -$-86.91M | -$-70.75M |
| Total assets | $280.7M | $376.7M | $462.3M | $380.6M | $440.9M |
| Total debt | $201.1M | $226.1M | $26.5M | $26.7M | $6.83M |
| Net debt | $168.8M | $188.8M | -$-58.88M | -$-17.31M | -$-50.37M |
| Total equity | $64.7M | $128.8M | $216.7M | $321.3M | $399.4M |
| Cash and short-term investments | $188.9M | $248.2M | $369.9M | $249.2M | $244M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $65.3M | $67.6M | $79.2M | $86.2M | $97.1M |
| Cost of revenue | $4.59M | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $60.7M | $67.6M | $79.2M | $86.2M | $97.1M |
| Research and development expenses | $106.7M | $131.5M | $163.5M | $164.5M | $174.1M |
| Selling, general and administrative expenses | $43.9M | $57.9M | $52.9M | $45.5M | $32.5M |
| Other expenses | -$-4.59M | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $146.1M | $189.3M | $216.4M | $210M | $206.7M |
| Cost and expenses | $150.7M | $189.3M | $216.4M | $210M | $206.7M |
| Interest income | $9.48M | $14.8M | $11.4M | $1.57M | $2.02M |
| Interest expense | $7.68M | $10.9M | $5.15M | $0.00 | $0.00 |
| Depreciation and amortization | $5.09M | $2.34M | $2.37M | $2.97M | $3.33M |
| Ebitda | -$-70.78M | -$-104.51M | -$-123.48M | -$-119.22M | -$-104.25M |
| Operating income | -$-85.35M | -$-121.69M | -$-137.21M | -$-123.84M | -$-109.57M |
| Total other income/expenses, net | $1.8M | $3.9M | $6.21M | $1.66M | $1.99M |
| Income before tax | -$-83.55M | -$-117.79M | -$-131M | -$-122.19M | -$-107.58M |
| Income tax expense | -$-1.66M | -$-1.74M | $2.82M | -$-430K | -$-28.58M |
| Net income | -$-81.89M | -$-116.05M | -$-133.82M | -$-121.75M | -$-79M |
| Weighted average shares outstanding | $21.3M | $21.2M | $21M | $20.6M | $20.2M |
| Weighted average diluted shares outstanding | $21.3M | $21.2M | $21M | $20.6M | $20.2M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $188.9M | $248.2M | $369.9M | $249.2M | $244M |
| Net receivables | $6.88M | $38.7M | $39.6M | $49M | $60.8M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $204.3M | $299.9M | $422.8M | $311.7M | $319M |
| Property, plant and equipment, net | $72.9M | $73.4M | $34.7M | $29.8M | $10.7M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $3.36M | $3.36M | $3.97M | $33.3M | $109M |
| Total non-current assets | $76.4M | $76.8M | $39.5M | $68.9M | $121.8M |
| Total assets | $280.7M | $376.7M | $462.3M | $380.6M | $440.9M |
| Accounts payable | $1.95M | $8M | $4.1M | $6M | $9.54M |
| Short-term debt | $33.9M | $36M | $5.28M | $2.89M | $4.2M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $48.6M | $57.5M | $62.8M | $29.8M | $36.2M |
| Long-term debt | $167.2M | $190.1M | $21.2M | $23.8M | $2.63M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $167.5M | $190.3M | $182.8M | $29.4M | $5.26M |
| Capital lease obligations | $57.9M | $55.5M | $26.5M | $25.3M | $5.33M |
| Total liabilities | $216M | $247.8M | $245.5M | $59.3M | $41.4M |
| Common stock | $210K | $210K | $210K | $210K | $200K |
| Retained earnings | -$-404.93M | -$-323.04M | -$-207M | -$-73.18M | $48.6M |
| Accumulated other comprehensive income (loss) | -$-340K | $300K | -$-1.17M | -$-3.72M | -$-380K |
| Total equity | $64.7M | $128.8M | $216.7M | $321.3M | $399.4M |
| Total investments | $159.9M | $214.3M | $288.5M | $238.5M | $295.8M |
| Total debt | $201.1M | $226.1M | $26.5M | $26.7M | $6.83M |
| Net debt | $168.8M | $188.8M | -$-58.88M | -$-17.31M | -$-50.37M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-81.89M | -$-116.05M | -$-133.82M | -$-121.75M | -$-79M |
| Depreciation and amortization | $5.09M | $2.34M | $2.37M | $2.97M | $3.33M |
| Stock-based compensation | $18.6M | $26.8M | $28.2M | $27M | $21M |
| Change in working capital | $39.9M | $7.13M | $8.02M | $6.79M | -$-13.69M |
| Accounts receivable | $31.8M | $970K | $9.42M | $11.8M | -$-24.3M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-1.31M | -$-410K | -$-1.15M | -$-4.63M | $3.77M |
| Net cash provided by operating activities | -$-19.27M | -$-78.76M | -$-103.15M | -$-84.78M | -$-70M |
| Investments in property, plant and equipment | -$-12.9M | -$-17.95M | -$-9.06M | -$-2.12M | -$-750K |
| Acquisitions, net | $0.00 | $0.00 | $44.5M | -$-54.9M | -$-37.74M |
| Net cash used for investing activities | $40.4M | $58.2M | -$-53.58M | $54.9M | $37M |
| Common stock issued | $140K | $150K | $2.21M | $21.3M | $3.61M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-26.62M | -$-27.63M | $198.1M | $20M | $3.08M |
| Net change in cash | -$-5.54M | -$-48.16M | $41.4M | -$-9.85M | -$-29.93M |
| Cash at end of period | $35.7M | $41.2M | $89.4M | $48M | $57.8M |
| Operating cash flow | -$-19.27M | -$-78.76M | -$-103.15M | -$-84.78M | -$-70M |
| Capital expenditure | -$-12.9M | -$-17.95M | -$-9.06M | -$-2.12M | -$-750K |
| Free cash flow | -$-32.17M | -$-96.71M | -$-112.21M | -$-86.91M | -$-70.75M |
Line items
Line items
Line items
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
- CEO
- Jay R. Luly
- Employees
- 120
- Beta
- 0.97
Included in
Explore
Frequently asked questions
What is the intrinsic value of Enanta Pharmaceuticals, Inc. (ENTA)?
Enanta Pharmaceuticals, Inc. (ENTA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ENTA undervalued?
ENTA trades at a price of $7.62 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.